Cybin Announces Successful Completion of In Vivo Preclinical Studies for its Deuterated Psilocybin Analog CYB003 Supporting Advancement into Phase 1/2a Clinical Trial

Cybin has completed in vivo preclinical studies evaluating its deuterated psilocybin analogue CYB003 for the potential treatment of major depressive disorder (MDD). 

Category Press Release
Published in The Dales Report

Companies Featured

Cybin is a for-profit company that aims to deliver psychedelics (psilocybin) via a sublingual delivery mechanism. The company aims to start clinical trials within the year (2021). It has raised $98 million US.